EU MDR Support
Support clinical and post-market evidence activities across the EU MDR lifecycle.
Needed at any stage of the EU MDR lifecycle — from pre-market clinical evidence planning through post-market surveillance and Notified Body queries.
Bioexcel aligns clinical strategy, clinical investigation, CER and post-market evidence activities to the specific MDR requirement in front of the manufacturer at that stage.
What Bioexcel Provides
- Clinical evidence strategy
- CER / CEP
- PMCF plan and report
- Notified Body response support
Integrates with CER, PMCF, PMS/PSUR and Notified Body deficiency support.
Preparing for More Predictable Conformity Assessments
Commission Implementing Regulation (EU) 2026/977 introduces more uniform requirements for Notified Body quotations, assessment stages, timelines and clock-stops. Manufacturers will still need complete, consistent and review-ready evidence to avoid delays attributable to documentation or evidence gaps. Bioexcel supports manufacturers through evidence-gap assessment, clinical and performance documentation, post-market evidence and Notified Body query remediation.
Source: European Commission — Commission Implementing Regulation (EU) 2026/977
Last Reviewed: 27 August 2026
Technical Reviewer: Named EU MDR / IVDR expert
This is a summary only and does not constitute regulatory advice. Regulatory requirements evolve — verify current requirements against the official EU source before relying on this content.
Typical Engagement Model
Discuss Your EU MDR Support Requirement
Share your program details and Bioexcel can help scope the right level of support.